CurrentRheuma — Spondyloarthritis & psoriatic arthritis

Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial

2026-11-11T17:15:37.180Z

Randomized controlled trial · Arthritis Rheumatol, 2026.

WTAP regulates PTEN through m6A methylation to modulate the inflammatory response in CD4+ T cells from patients with ankylosing spondylitis

2026-11-09T17:15:24.911Z

Case-control study · Clin Exp Rheumatol, 2026.

Clinical phenotype, disease burden and inter-regional heterogeneity of axial spondyloarthritis in 1112 patients across 15 Arab countries: the PROSPA study

2026-11-06T09:16:48.334Z

Cross-sectional study · RMD Open, 2026.

Diffuse idiopathic skeletal hyperostosis is associated with reduced lung function independent of structural lung abnormalities

2026-11-05T16:08:02.128Z

Research article · Semin Arthritis Rheum, 2026.

A CCL20+ macrophage subpopulation is the major producer of TNF in axial spondyloarthritis synovium and is driven by CD40L and a myeloid autocrine circuit

2026-11-05T13:24:18.717Z

Research article · Ann Rheum Dis, 2026.

Bimekizumab-Treated Patients with Axial Spondyloarthritis Maintained Stringent Clinical Responses Over 3 Years: Phase 3 and Open-Label Extension Results

2026-11-05T13:24:18.717Z

Secondary analysis · J Rheumatol, 2026.

Does weather matter? Exploring associations between season and meteorological factors and psoriatic arthritis disease activity

2026-11-05T13:24:18.717Z

Cohort study · RMD Open, 2026.

Performance of MRI-based synthetic CT for detecting spinal new bone formation in patients with inflammatory arthritis and healthy controls: a comparison with MRI, CT, and radiography

2026-11-05T13:24:18.717Z

Diagnostic or prognostic study · Ann Rheum Dis, 2026.

Predictors of b/tsDMARDs discontinuation and treatment response in psoriatic arthritis: results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR-PsA)

2026-11-05T13:24:18.717Z

Cohort study · Rheumatology (Oxford), 2026.

Real‑world assessment of the effectiveness and response profiles of biologic DMARDs in psoriatic arthritis: findings from an emulated multicentre clinical trial

2026-11-05T13:24:18.717Z

Research article · Ann Rheum Dis, 2026.

The development and validation of a new diagnostic sonographic enthesitis score for psoriatic arthritis: Diagnostic Ultrasound Enthesitis Tool ( DUET )

2026-11-05T13:10:58.883Z

Diagnostic or prognostic study · Arthritis Rheumatol, 2026.

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

2026-11-04T23:57:40.771Z

Randomized controlled trial · Lancet, 2022. ACR50, up to week 16: Bimekizumab 116 (43%) · Placebo 9 (7%)

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

2026-11-04T23:57:40.771Z

Randomized controlled trial · Lancet, 2022. ACR50 response, up to week 16: Bimekizumab 189 (44%) · Placebo 28 (10%) · Adalimumab 64 (46%)

Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Anti-SARS-CoV-2 IgG level after booster dose, 15 days after third shot: PsA 15846.47 (± 12876.48) AU/ml · Controls 20374.46 (± 12797.08) AU/ml

Association of circulating lymphocyte subsets with response to IL17i and TNFi in axial spondyloarthritis

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2021. Circulating lymphocyte subsets, axSpA vs HC, baseline — axSpA vs HC; p<0.003 after correction; reduced/increased frequencies of 10/27 subsets; trends for another 5

Clinical and laboratory factors associated with the bamboo spine in patients with axial spondyloarthritis: are there clues for the bamboo spine?

2026-11-04T23:43:54.165Z

Cross-sectional study · Clin Exp Rheumatol, 2021. Factors associated with bamboo spine: Bamboo spine prevalence among patients with eligible radiographs 111 (8.9%)

Confounders contributing to explain the association between sex and disease impact in patients with recent-onset psoriatic arthritis

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. PsAID ≥4, adjusted for HAQ, global pain, physical activity level and joint pattern at diagnosis: No statistically significant association between female sex and PsAID ≥4 after adjustment

Depression and anxiety in a real-world psoriatic arthritis longitudinal study: should we focus more on patients' perception?

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. first visit: Prevalence of depression 19.5%

Differentiating patients with psoriasis from psoriatic arthritis using collagen biomarkers

2026-11-04T23:43:54.165Z

Cross-sectional study · Clin Exp Rheumatol, 2022. Serum collagen biomarkers — PsC vs Healthy donors; p<0.05-p<0.0001; PRO-C1 and C3M lower in PsC and PsA vs healthy controls

Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study

2026-11-04T23:43:54.165Z

Secondary analysis · Clin Exp Rheumatol, 2022. Dactylitis at baseline: Patients with dactylitis at baseline 389/996 (39%)

Impact of psoriasis remains important in psoriatic arthritis patients with low musculoskeletal disease activity

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. HRQoL, one year — Active psoriasis vs Psoriasis remission; p=0.012; Active psoriasis scored lower on PsAID-12

Machine-learning derived algorithms for prediction of radiographic progression in early axial spondyloarthritis

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. 10-fold cross-validated AUC for prediction of radiographic progression: M2 0.79; cv-AUC 0.79 · M3 0.78; cv-AUC 0.78 · GAM 0.77; cv-AUC 0.77 · DBARTS 0.76; cv-AUC 0.76 · Super Learner 0.74; cv-AUC 0.74

Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Treatment persistence, up to 12±3 months: Ustekinumab 74.3% · TNFi 63.6%

Response to netakimab in radiographic axial spondyloarthritis patients with different baseline C-reactive protein, sacroiliitis evaluated by MRI and peripheral joint involvement status: a post-hoc analysis of the ASTERA study

2026-11-04T23:43:54.165Z

Secondary analysis · Clin Exp Rheumatol, 2022. Response to netakimab by subgroup, week 16: Improvement in all outcomes similar for MRI-SI- and MRI-SI+, except change in ASspi-MRI-a significantly greater in MRI-SI+

Serum leptin concentration is associated with the attainment of clinical outcomes in patients with axial spondyloarthritis treated with TNF inhibitors

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. 6 m: Remission attained 24%

Costovertebral joint involvement in patients with axial spondyloarthritis

2026-11-04T23:42:37.367Z

Cross-sectional study · Joint Bone Spine, 2023. Costovertebral joint abnormalities: Reader 1: patients with costovertebral joint abnormalities 74 (49%)

Differences between early vs. late-onset of psoriatic arthritis: Data from the RESPONDIA and REGISPONSER registries

2026-11-04T23:42:37.367Z

Cross-sectional study · Joint Bone Spine, 2023. Factors independently associated with late-onset PsA (logistic regression) — Late onset vs Early onset: OR (male sex) 4.4 (95% CI 1.3, 16.3)

Evaluating remission and low disease activity from the perspective of the patient with axial spondyloarthritis: The cross-sectional ConREspAx study

2026-11-04T23:42:37.367Z

Cross-sectional study · Joint Bone Spine, 2022. Patients: Remission 21%; LDA 51.4% · Physicians: Remission 45.7%; LDA 35.2%

Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and Europe

2026-11-04T23:42:37.367Z

Cross-sectional study · Joint Bone Spine, 2023. Mean EQ VAS score by manifestation: With vs without enthesitis 59.9 vs. 75.6

Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis

2026-11-04T23:42:37.367Z

Cohort study · Joint Bone Spine, 2022. Anti-SARS-CoV-2 IgG SP, D69: SpA 80.2% · CG 95.7%

Post-traumatic stress disorder prior to diagnosis is as rare in spondyloarthritis as in non-inflammatory rheumatic conditions and rheumatoid arthritis

2026-11-04T23:42:37.367Z

Cross-sectional study · Joint Bone Spine, 2022. PTSD prevalence: SpA 4.9%

The impact of diet on disease activity in spondyloarthritis: A systematic literature review

2026-11-04T23:42:37.367Z

Cohort study · Joint Bone Spine, 2022. Effect of diet/dietary supplements on SpA disease activity: Probiotics in SpA: 2 RCTs (one unclear, one low RoB) failed to show benefit

Does a short course of etanercept influence disease progression and radiographic changes in patients suspected of non-radiographic axial spondyloarthritis? Three -years follow- up of a placebo-controlled trial

2026-11-04T23:40:51.898Z

Randomized controlled trial · Scand J Rheumatol, 2022. Disease activity (BASDAI, ASDAS) at 3 years, initial randomisation groups, up to 3 years: BASDAI, mean difference between initial randomisation groups 0.9 (95% CI -1.1;0.7, p = 0.6)

Implementing enhancements in supervised group exercise for people with axial spondyloarthritis: a hybrid effectiveness–implementation study

2026-11-04T23:40:51.898Z

Research article · Scand J Rheumatol, 2021. Effects of SGE enhancements: aerobic capacity (6MWT), physical functioning (ASPI), health status (ASAS HI) and home exercise engagement (SQUASH), baseline vs 1 year, after one year: Aerobic capacity (6MWT) increased significantly

Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland

2026-11-04T23:40:51.898Z

Cohort study · Scand J Rheumatol, 2023. Apremilast persistence, observation period — Prior biologic therapy vs Prior conventional synthetic therapy: HR for discontinuation 2.15 (95% CI 1.42-3.25)

Relationship between sex and clinical and imaging features of early axial spondyloarthritis: results from a 48 month follow-up (Italian arm of the SPondyloArthritis Caught Early (SPACE) study)

2026-11-04T23:40:51.898Z

Cohort study · Scand J Rheumatol, 2023. Males younger, shorter axial symptom duration, more often HLA-B27 positive, radiographic sacroiliitis with bilateral/symmetric pattern, more signs of spondylitis

Worse scores but similar patterns of disease activity: interpreting outcomes in women with axial spondyloarthropathy

2026-11-04T23:40:51.898Z

Cross-sectional study · Scand J Rheumatol, 2022. BASDAI score: Females 4.57 · Males 3.83

Cigarette Smoking Increases the Prevalence of Hip Joint Involvement in Ankylosing Spondylitis: A Real-World Case-Control Study

2026-11-04T23:37:51.551Z

Case-control study · J Rheumatol, 2023. Hip involvement, independent associations (adjusted): Cigarette smoking, aOR 7.23 (95% CI 2.27-23.05)

Clinically Relevant Deficits in Performance Tests in Patients With Axial Spondyloarthritis

2026-11-04T23:37:51.551Z

Cross-sectional study · J Rheumatol, 2022. Impairment in performance tests: Impairment in ≥ 1 performance test 91 patients (45.5%)

Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials

2026-11-04T23:37:51.551Z

Diagnostic or prognostic study · J Rheumatol, 2023. ASAS HI clinimetric properties: COAST-V: ICC test-retest reliability 0.78 · COAST-W: ICC test-retest reliability 0.76

Development and Validation of a Self-Administered Questionnaire Measuring Essential Knowledge in Patients With Axial Spondyloarthritis

2026-11-04T23:37:51.551Z

Diagnostic or prognostic study · J Rheumatol, 2022. SPAKE long-form knowledge score (0 to 100): Mean (SD) long-form score 71.6 (15.4)

Doppler Signal and Bone Erosions at the Enthesis Are Independently Associated With Ultrasound Joint Erosive Damage in Psoriatic Arthritis

2026-11-04T23:37:51.551Z

Cross-sectional study · J Rheumatol, 2022. Variables associated with US-detected joint bone erosions (multivariate model): Power Doppler (PD) signal at the enthesis, standardized β (P < 0.001) 0.51

Evaluation of Standard and Proposed Reference Values for Entheseal Thickening by Using Musculoskeletal Ultrasound

2026-11-04T23:37:51.551Z

Diagnostic or prognostic study · J Rheumatol, 2022. Entheseal thickening by current cut-offs (% of entheses): HCs 196 (20.4%) · axSpA 396 (33%)

Impact of Physician-Defined Flares on Quality of Life and Work Impairment: An International Survey of 2238 Patients With Psoriatic Arthritis

2026-11-04T23:37:51.551Z

Cross-sectional study · J Rheumatol, 2022. PROs by flare status: No flare in last 12 months or never flared: higher QOL, lower overall work impairment and lower disability vs current flare all; P < 0.01

Inflammatory Bowel Disease Risk in Patients With Axial Spondyloarthritis Treated With Biologic Agents Determined Using the BSRBR-AS and a MetaAnalysis

2026-11-04T23:37:51.551Z

Meta-analysis · J Rheumatol, 2022. Incidence of IBD, BSRBR-AS (IRD per 1000 PY) — Biologic therapy vs Not exposed to biologic therapy: IRD 11.9 per 1000 PY (95% CI 4.3-19.6)

Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program

2026-11-04T23:37:51.551Z

Randomized controlled trial · J Rheumatol, 2023. Efficacy in patients receiving IXE Q4W, 3 years: All patient groups receiving IXE Q4W saw sustained improvements in ASDAS, clinically important improvement, and other efficacy end points

Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

2026-11-04T23:37:51.551Z

Meta-analysis · J Rheumatol, 2022. New bDMARD and tsDMARD classes, IL-17A and JAK inhibitors, could be considered for treatment of axPsA

Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients With Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations

2026-11-04T23:37:51.551Z

Meta-analysis · J Rheumatol, 2022. Efficacy and safety of advanced therapies in CD, UC and uveitis: Eligible RCTs: 12 for CD, 15 for UC, 5 for uveitis

Management of Dactylitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

2026-11-04T23:37:51.551Z

Research article · J Rheumatol, 2022. Dactylitis assessment in RCTs reporting dactylitis-related outcomes: Dactylitis assessed as a secondary outcome 97.5%

Management of Enthesitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

2026-11-04T23:37:51.551Z

Meta-analysis · J Rheumatol, 2022. Enthesitis treatment response: 41 RCTs included; each intervention graded